Table 2.
Trends in the incidence rates of Waldenström macroglobulinemia (1980–2016): the SEER-9 registry database.
| Trend | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall (1980–2016) | 1 | 2 | 3 | 4 | 5 | ||||||
| AAPC (95% CI) | Year | APC (95% CI) | Year | APC (95% CI) | Year | APC (95% CI) | Year | APC (95% CI) | Year | APC (95% CI) | |
| Overall | 5.2* (3.8 to 6.6) | 1980–1993 | 14.1* (10 to 18.4) | 1993–2016 | 0.5 (−0.3 to 1.3) | ||||||
| Age, years | |||||||||||
| <50 | 0.7 (−1.7 to 3.1) | 1980–1997 | 5.4* (1.1 to 9.9) | 1997–2016 | −3.4* (−6.1 to −0.7) | ||||||
| 50–59 | 2.2* (0.8 to 3.7) | 1980–2000 | 7.0* (4.6 to 9.4) | 2000–2016 | −3.4* (−5.1 to −1.6) | ||||||
| 60–69 | 4.7* (3.1 to 6.3) | 1980–1996 | 11.6* (8 to 15.3) | 1996–2016 | −0.5 (−1.7 to 0.7) | ||||||
| 70–79 | 7.2* (5 to 9.5) | 1980–1992 | 19.3* (12.1 to 27.1) | 1992–2016 | 1.6* (0.7 to 2.6) | ||||||
| 80+ | 6.5* (3.3 to 9.9) | 1980–1990 | 20.9* (8 to 35.3) | 1990–2016 | 1.5* (0.4 to 2.6) | ||||||
| Sex | |||||||||||
| Male | 5.4* (3.7 to 7.1) | 1980–1993 | 14.8* (9.9 to 20) | 1993–2016 | 0.4 (−0.5 to 1.3) | ||||||
| Female | 4.9* (3.4 to 6.5) | 1980–1993 | 13.2* (8.9 to 17.7) | 1993–2016 | 0.5 (−0.4 to 1.4) | ||||||
| Race | |||||||||||
| White | 5.6* (4.1 to 7.2) | 1980–1993 | 14.8* (10.4 to 19.4) | 1993–2016 | 0.7 (−0.1 to 1.6) | ||||||
| Black | 0.4 (−0.9 to 1.7) | 1980–2016 | 0.4 (−0.9 to 1.7) | ||||||||
| Other | 0.4 (−0.9 to 1.7) | 1980–2016 | 0.4 (−0.9 to 1.7) | ||||||||
| Geographical region | |||||||||||
| East | 2.4 (−1.4 to 6.4) | 1980–1985 | −12.5 (−30.1 to 9.5) | 1985–1995 | 13.3* (3.9 to 23.6) | 1995–2016 | 1.3* (0.1 to 2.6) | ||||
| Northern plains | 5.4* (3.7 to 7.1) | 1980–1991 | 18.1* (12 to 24.5) | 1991–2016 | 0.3 (−0.6 to 1.1) | ||||||
| Pacific coast | 6.5* (3.2 to 9.9) | 1980–1989 | 23.1* (9.4 to 38.4) | 1989–2004 | 4.2* (1.5 to 6.9) | 2004–2016 | −1.7 (−4.2 to 0.9) | ||||
| Southwest | −0.8 (−2.6 to 1.1) | 1982–2016 | −0.8 (−2.6 to 1.1) | ||||||||
| Primary site of involvement | |||||||||||
| Bone marrow | 17.9* (11.1 to 25.1) | 1980–1988 | 96.5* (49 to 159.2) | 1988–2016 | 1.9* (1.4 to 2.4) | ||||||
| Extramedullary disease | −0.7 (−5.1 to 4) | 1980–1991 | −2.1 (−5.9 to 1.8) | 1991–1998 | 11.2* (3.5 to 19.5) | 1998–2009 | −0.3 (−3 to 2.4) | 2009–2012 | −25.6 (−54.3 to 21.2) | 2012–2016 | 4.4 (−9.9 to 20.8) |
| Subtype | |||||||||||
| Lymphoplasmacytic lymphoma | 1.7 (−0.7 to 4.2) | 1980–1990 | −2.7 (−8.3 to 3.3) | 1990–1998 | 10.9 *(2.6 to 19.9) | 1998–2016 | 0.2 (−1.1 to 1.6) | ||||
| Waldenström macroglobulinemia | 16.5* (6.8 to 27) | 1980–1988 | 95.9* (30.1 to 194.9) | 1988–2016 | 0.4 (−0.2 to 1) | ||||||
*
P < 0.05.
APC, annual percentage change; SEER, Surveillance, Epidemiology, and End Results database.